The Supreme Court has unanimously ruled that generic drugmakers cannot be sued for patent infringement simply because their marketing materials don’t spell out every limitation of their FDA approval — a decision that clears a significant legal cloud over a strategy used to bring cheaper drugs to market faster.
The June 4 ruling in Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc. resolves a dispute that had put a common generic drug launch strategy at risk. When a brand-name drug holds patents on some uses but not others, generic manufacturers can win FDA approval for only the unpatented uses — a so-called “skinny label” — and begin selling a cheaper version without waiting for all patents to expire. The approach has saved Medicare an estimated $15 billion between 2015 and 2021, according to a 2024 study in the Annals of Internal Medicine, and underlies nearly half of all first-to-market generic launches.
The case arose after Hikma Pharmaceuticals launched a generic version of Amarin’s heart drug Vascepa under a skinny label approved only for one use. Amarin sued, arguing that because Hikma described its product as a “generic version” of Vascepa in press releases and on its website — without flagging that it was approved for fewer uses — it was effectively nudging doctors to prescribe the drug for a still-patented indication.
The Supreme Court disagreed. Writing for a unanimous court, Justice Ketanji Brown Jackson said the law requires proof that a company actively pushed physicians toward the patented use, not just that a doctor could have drawn that inference on their own. Calling a product a “generic version” of a brand-name drug, or following standard industry marketing practices, isn’t enough to cross that line.
For hospital pharmacy leaders, the ruling matters beyond this one drug. A loss for Hikma would have made skinny labeling legally risky for generic manufacturers, likely delaying cheaper alternatives to brand-name drugs with multiple patents — and keeping costs higher for health systems and patients longer.
